MOHAMED KHODEIR: Open Payments
NPI 1801843024 · COLUMBUS, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,526 in 108 payments from 10 companies in 2025. Trend: 2023 $943 · 2024 $1,530 · 2025 $1,526
Food & beverage: $1,303Education: $223
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 36 | $737 |
| E.R. Squibb & Sons, L.L.C. | 18 | $293 |
| ABBVIE INC. | 41 | $216 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $115 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Neurocrine BioSciences, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
| Alkermes, Inc. | 1 | $16 |
| Janssen Pharmaceuticals, Inc | 1 | $15 |
Products named: UZEDY, COBENFY, VRAYLAR, CAPLYTA, INGREZZA, ABILIFY ASIMTUFII, Auvelity, ERZOFRI EXTENDED-RELEASE.
Industry payments across OH — which companies pay providers there.
